^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tyvyt (sintilimab)

    i
    Other names: IBI308, IBI 308, IBI-308, LY-3342901
    Company:
    Eli Lilly, Innovent Biologics, Mankind Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=52, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    3d
    A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • lancastotug (AK127)
    3d
    B2019-148: Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2027
    Enrollment closed • Trial completion date
    |
    gemcitabine • Tyvyt (sintilimab) • oxaliplatin • Oncaspar liquid (pegaspargase)
    12d
    Long-term durable response to Sintilimab therapy in synchronous lung squamous cell carcinoma and gastric adenocarcinoma: a rare case report. (PubMed, Front Oncol)
    He was treated with Sintilimab plus Anlotinib, resulting in lung lesion regression. Both tumors showed high proliferative indices (Ki-67 ~80-90%) and PD-L1 expression, supporting responsiveness to immune checkpoint blockade. This case highlights the feasibility of immune monotherapy in managing complex synchronous malignancies, especially when standard treatments are declined.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    14d
    A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    Tyvyt (sintilimab) • Yutuo (zimberelimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    15d
    A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Tyvyt (sintilimab)
    17d
    Economic value, affordability, and scale-up of adjuvant immunotherapies in lung cancer treatment: From cost-effectiveness decision to budget impact analysis. (PubMed, J Cancer Policy)
    Adjuvant immunotherapies for lung cancer deliver meaningful clinical benefits, but their economic value and affordability are highly context-specific. While several strategies are cost-effective at the individual patient level, health system affordability is strongly influenced by the pace and scale of adoption. Scenario-based budget impact analyses demonstrate that accelerated uptake can impose substantial short-term fiscal pressure, whereas phased or restricted implementation markedly improves affordability without altering cost-effectiveness conclusions. These findings underscore the importance of integrating cost-effectiveness evidence with explicit consideration of budget impact, adoption strategies, and managed entry mechanisms to support sustainable and equitable scale-up of adjuvant immunotherapies in routine clinical practice.
    Review • Journal • HEOR • PD(L)-1 Biomarker • IO biomarker • Cost-effectiveness
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Conmana (icotinib) • Cejemly (sugemalimab)
    17d
    Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Tongji Hospital
    New P2 trial
    |
    CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FGF4 (Fibroblast growth factor 4)
    |
    Keytruda (pembrolizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib)
    17d
    Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Jaypirca (pirtobrutinib) • thiotepa
    18d
    PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases (clinicaltrials.gov)
    P1, N=25, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial • pMMR
    |
    Tyvyt (sintilimab)
    18d
    Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=446, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Dec 2025 --> Dec 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF wild-type • RAS mutation
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin
    21d
    Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=54, Recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel